Compare Abeona Therapeutics Inc (ABEO) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Norwegian Cruise Line Holdings Ltd trades at $18.91 (market cap $8.59B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 20.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | NCLH | |
|---|---|---|
Market Cap | $421.19M | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $26.94 |
52-Week Low | $4.17 | $14.79 |
Enterprise Value | $276.10M | $23.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
NCLH trades at $18.93, up 2.05% today, with a bearish technical signal but strong fundamentals including a P/E of 11.33 and net income margin of 7.49%. Recent Q2 2026 earnings beat expectations at $0.48 per share, though revenue growth faces headwinds from high costs. Analyst consensus is a buy with a $20.73 price target, but news highlights concerns over fuel expenses and demand.
The outlook is mixed: valuation metrics suggest upside potential, but risks from macroeconomic pressures and execution challenges persist. Investors may find opportunity if turnaround plans gain traction, yet volatility from operational costs and travel demand fluctuations warrants caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
